About Otsuka
Otsuka is a company based in Chiyoda (Japan) founded in 1921. The company has 35,340 employees as of December 31, 2024. Otsuka has completed 8 acquisitions, including Astex Pharmaceuticals, Avanir and Daiya Foods. Otsuka offers products and services including Medications and Functional Beverages.
- Headquarter Chiyoda, Japan
- Employees 35340 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Otsuka Holdings Co., Ltd.
-
Annual Revenue
$14.84 B (USD)15.42as on Dec 31, 2024
-
Net Profit
$2.19 B (USD)182.13as on Dec 31, 2024
-
EBITDA
$3.22 B (USD)29.45as on Dec 31, 2024
-
Latest Funding Round
Not available
- Investors
-
Employee Count
35340
as on Dec 31, 2024
-
Investments & Acquisitions
Astex Pharmaceuticals
& 7 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Otsuka
Otsuka is a publicly listed company on the TSE with ticker symbol 4578 in Japan, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Otsuka
Otsuka offers a comprehensive portfolio of products and services, including Medications and Functional Beverages.
Innovative medications are developed and supplied for various health applications
Functional beverages and foods are produced to support nutritional needs worldwide
People of Otsuka
Unlock access to complete
Unlock access to complete
Leadership Team
38 people
Board Team
8 people
Software Development Team
7 people
Product Management Team
6 people
Sales and Marketing
5 people
Senior Team
5 people
Human Resources and Administration
4 people
Health Team
3 people
Unlock access to complete
Funding Insights of Otsuka
Investors in Otsuka
Otsuka has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Gates Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Charitable foundation investments on poverty reduction and healthcare
|
Locked | Locked | Locked |
Investor details for Otsuka
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Otsuka
Otsuka has strategically engaged in corporate development activities, having acquired 8 companies. Notable acquisitions include Astex Pharmaceuticals, Avanir and Daiya Foods.
Investment portfolio details for Otsuka
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Neurochemical modulators for ADHD treatment are developed by Neurovance.
|
Locked | Locked | 2011 | Locked | |
|
Ultrasound-based renal denervation is applied for hypertension treatment.
|
Locked | Locked | 2009 | Locked | |
|
Dairy-free cheese alternatives are produced and marketed by Daiya Foods.
|
Locked | Locked | 2008 | Locked |
Complete acquisition details for Otsuka
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Otsuka
Detailed financials for Otsuka
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Otsuka Comparisons
Peer comparison for Otsuka
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Otsuka
Detailed competitors of Otsuka
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Otsuka
Complete news archive for Otsuka
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Otsuka
Otsuka was founded in 1921 and raised its 1st funding round 100 years after it was founded.
Otsuka is headquartered in Chiyoda, Japan. It is registered at Chiyoda, Tokyo, Japan.
Tatsuo Higuchi is the current CEO of Otsuka.
As of Dec 31, 2024, the latest employee count at Otsuka is 35,340.
Annual revenue of Otsuka is $14.84B as on Dec 31, 2024.
Otsuka was founded in 1921 in Chiyoda City, Japan, as a manufacturer in the pharmaceutical and nutraceutical sectors. Generic drugs are produced and distributed, targeting central nervous system, cardiovascular, oncology, and ophthalmology areas. Avanir Pharmaceuticals, a US firm, was acquired in January 2015 to expand operations. Nutraceutical offerings include electrolyte rehydration drinks, balanced nutrition foods, and soy-based products. Revenues reached 13.21 billion with 1.02 billion in net profit for 2022.
Otsuka offers Medications and Functional Beverages.
Yes, Otsuka is publicly traded on TSE under the ticker symbol 4578.
Otsuka has made 8 acquisitions, including Astex Pharmaceuticals, Avanir, and Daiya Foods.
Otsuka has 1 investor. Key investors include Gates Foundation.
The ticker symbol of Otsuka is 4578 on TSE.